Clinical Trial Update: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nivolumab alone or in combination with cabozantinib to prevent recurrence of mucosal melanoma after surgery; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anal Melanoma, Bladder Melanoma | Phase 2 | Status: RECRUITING